Palisade Bio Provides Update On Progress Toward Launch Of Phase 1 Human Clinical Study For Lead Program, PALI-2108 For The Treatment Of Ulcerative Colitis; On Track Towards Clinical Site Initiation And Dosing Of First Patient In Phase 1 Human Clinical Study Before Year End
Portfolio Pulse from Benzinga Newsdesk
Palisade Bio is progressing towards the launch of a Phase 1 clinical study for its lead program, PALI-2108, aimed at treating ulcerative colitis. The company has completed necessary preclinical studies and is on track to initiate clinical site and dosing by year-end.
September 25, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Palisade Bio is advancing its lead program, PALI-2108, for ulcerative colitis treatment, with Phase 1 trials expected to start by year-end. This progress could enhance investor confidence and potentially impact stock positively.
The completion of preclinical studies and the upcoming initiation of Phase 1 trials for PALI-2108 are significant milestones. These developments suggest progress in the company's pipeline, which could positively influence investor sentiment and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100